Previous Article | Next Article 
Journal of Clinical Microbiology, December 2001, p. 4440-4444, Vol. 39, No. 12
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.12.4440-4444.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Evaluation of BACTEC Mycobacteria Growth Indicator
Tube (MGIT 960) Automated System for Drug Susceptibility Testing of
Mycobacterium tuberculosis
Fausta
Ardito,1
Brunella
Posteraro,1
Maurizio
Sanguinetti,1,*
Stefania
Zanetti,2 and
Giovanni
Fadda1
Istituto di Microbiologia, Università
Cattolica del Sacro Cuore, Rome,1 and
Dipartimento di Scienze Biomediche, Sezione di Microbiologia,
Università di Sassari, Sassari,2 Italy
Received 25 June 2001/Returned for modification 30 August
2001/Accepted 2 October 2001
 |
ABSTRACT |
The reliability of the BACTEC MGIT 960 system, an automated version
of the Mycobacteria Growth Indicator Tube (MGIT), for antimicrobial
susceptibility testing of Mycobacterium tuberculosis was
evaluated on 78 clinical isolates. Rifampin (RMP), isoniazid (INH),
streptomycin (SM), and ethambutol (EMB) were tested at the following
concentrations: 1.0 µg/ml for RMP, 0.1 and 0.4 µg/ml for INH, 1.0 and 4.0 µg/ml for SM, and 5.0 and 7.5 µg/ml for EMB. Results were
compared with those obtained by the BACTEC 460 TB radiometric system.
Initially the reproducibility study showed 99.5% agreement on repeat
testing with all the four drugs. With susceptibility testing of
clinical isolates, excellent agreement between the two systems was
found for all the drugs. A total of nine major errors were observed for
only three isolates, resistant according to BACTEC MGIT 960 and
susceptible according to BACTEC 460 TB, to SM (4.0 µg/ml), INH (0.1 µg/ml), and EMB (5.0 µg/ml) (one isolate) and to SM (1.0 µg/ml),
INH (0.4 µg/ml), and EMB (5.0 µg/ml) (two isolates). When these
isolates were tested by using the conventional proportion method on
Löwenstein-Jensen medium, agreement with BACTEC MGIT 960 was found for five results and with BACTEC 460 TB for the remainder.
The time to report results was 7.9 days by MGIT 960 and 7.3 days by
BACTEC 460 TB, which was not found statistically significant
(P > 0.05). In conclusion, the performance of BACTEC
MGIT 960 was found similar to that of BACTEC 460 TB and this new system
can be considered a good alternative to the radiometric method for
routine susceptibility testing of M. tuberculosis.
 |
INTRODUCTION |
Drug-resistant Mycobacterium
tuberculosis strains represent a serious public health problem.
Resistance to the four primary drugs, streptomycin (SM), isoniazid
(INH), rifampin (RMP), and ethambutol (EMB) (a combination known as
SIRE), makes tuberculosis difficult to treat (19).
Multidrug-resistant strains have emerged within the last decade, and
the rapid detection of these isolates is critical for the effective
treatment of patients (28). As recommended by the National
MDR TB Task Force, to combat multidrug-resistant tuberculosis
(7), antimicrobial susceptibility testing (AST) must be
performed on all initial and follow-up M. tuberculosis isolates from each patient. Among the methods used for drug
susceptibility testing, the agar proportion method (MOP) is universally
accepted as the "gold standard" (18, 33). However, it
requires a long time to report (generally 21 days after the test is set
up). Since 1980 the BACTEC 460 TB radiometric system (Becton Dickinson
Diagnostic Instruments, Sparks, Md.), which is based on the modified
version of the proportion method (26), has been introduced
to perform AST. The BACTEC 460 TB method provides results within 5 to 6 days, with a significant time savings. Several studies
(25) have demonstrated that AST results obtained by BACTEC
460 TB were comparable with those of MOP, thus suggesting that the
former method could be adopted for routine laboratory purposes. In
1995, the Mycobacteria Growth Indicator Tube (MGIT, 4 ml) (Becton
Dickinson) was introduced for the growth and detection of mycobacteria
from clinical specimens (3, 8, 12). This method overcomes
the drawbacks of the BACTEC 460 TB system, such as the use of
radioactive substance and needles. The new MGIT medium consists of
modified Middlebrook 7H9 broth in a test tube with silicon rubber
impregnated with a fluorescence-quenching oxygen sensor. The
reliability of this manual MGIT for AST of M. tuberculosis
was recently evaluated and compared with the BACTEC 460 TB system,
suggesting that the MGIT system could be considered a good alternative
to the BACTEC 460 TB radiometric system (3, 5, 6, 20-22,
31).
With use of the MGIT technology, a fully automated system (BACTEC MGIT
960 [Becton Dickinson]), which is able to continuously monitor the
fluorescence due to growing mycobacteria (1, 11, 14, 29,
32) has been introduced recently. Also for this system, a
modified version of the conventional MOP has been developed, in order
to test the susceptibility of M. tuberculosis to the four
frontline drugs, SIRE.
In this study, we evaluated the performance of the BACTEC MGIT 960 in
testing antimicrobial susceptibility to SIRE in comparison to that of
the BACTEC 460 TB system by analyzing 78 M. tuberculosis clinical isolates. Discrepant results were resolved by the conventional MOP using Löwenstein-Jensen (LJ) medium.
 |
MATERIALS AND METHODS |
Study design.
The reliability of BACTEC MGIT 960 in testing
of M. tuberculosis susceptibility to the first-line drugs
SIRE was evaluated and compared to that of BACTEC 460 TB. The study
consisted of three phases: reproducibility, clinical isolate testing,
and resolution of discordant results. With the exception of RMP, two
concentrations (low and high) were used for all of the drugs tested.
Strains and inoculum.
A total of 78 M. tuberculosis isolates were included in the study. Sixty-six
strains were obtained from primary isolation cultures in the MGIT
medium, while 12 came from the stock culture collection. Strains were
identified by conventional biochemical methods (15) and by
PCR-reverse cross blot hybridization (23). For isolates
initially grown in MGIT medium, inoculum was prepared from the positive
culture on the 1st day of positivity as detected by the BACTEC MGIT 960 instrument. After being mixed well, 0.5 ml of the positive broth
cultures was used for BACTEC MGIT 960 AST (see below). For isolates
initially grown on LJ medium, a suspension of the microorganism was
prepared in 7H9 medium at a density of 0.5 McFarland and was then
diluted (1:5) with sterile saline. One-half milliliter of this dilution
was used for BACTEC MGIT 960 AST.
Drug solutions.
For AST using BACTEC MGIT 960, 4 ml of
sterile distilled water was added to a lyophilized vial containing the
low concentration of each drug (Becton Dickinson). Part of this
solution (0.1 ml) was aseptically pipetted into an MGIT tube to obtain
the following final drug concentrations in the medium (low or critical
concentrations): 1.0 µg/ml for SM, 0.1 µg/ml for INH, 1.0 µg/ml
for RMP, and 5.0 µg/ml for EMB. In addition, for SM, INH, and EMB,
stock solutions at higher concentrations were prepared by dissolving
each high-concentration lyophilized drug (Becton Dickinson) in 2 ml of
sterile distilled water. Part of this antibiotic solution (0.1 ml) was
transferred into the MGIT tube, yielding the final drug concentrations
(high) of 4.0 µg/ml for SM, 0.4 µg/ml for INH, and 7.5 µg/ml for
EMB. AST using the BACTEC 460 TB system was performed according to the
manufacturer's instructions (see below). Final drug concentrations were 2.0 and 6.0 µg/ml for SM, 0.1 and 0.4 µg/ml for INH, 2.0 µg/ml for RMP, and 2.5 and 7.5 µg/ml for EMB.
BACTEC MGIT 960 AST.
To each 7-ml MGIT tube, 0.8 ml of MGIT
960 Growth Supplement and 0.1 ml of the drug stock solution were
aseptically added, and finally 0.5 ml of the test inoculum was added.
For each isolate, a growth control (GC) tube with Growth Supplement and
without drug was included. For this GC the inoculum was prepared by
pipetting 0.1 ml of the test inoculum with 10 ml of sterile saline to
make a 1:100 dilution; 0.5 ml of GC inoculum was added to a drug-free MGIT tube. All of the inoculated tubes (seven drug-containing tubes and
one drug-free tube for each isolate) were placed into the BACTEC MGIT
960 instrument on the same day of inoculation. The relative growth
ratio between the drug-containing tube and drug-free GC tube was
determined by the system's software algorithm. If the relative growth
in the drug-containing tube was equal to or exceeded that of the GC
tube, the isolate was considered drug resistant; if the relative growth
was less than in the GC tube, the isolate was considered drug
susceptible. The instrument did the final interpretation and reported
the susceptibility results automatically.
BACTEC 460 TB AST.
From each positive MGIT tube, 0.5 ml was
inoculated into a BACTEC 12B vial. When the broth culture reached a
growth index of
500, the BACTEC 460 TB AST was performed according to
the manufacturer's recommendations (24).
Quality controls.
To test each new lot of MGIT tubes, BACTEC
460 TB vials, MGIT, and Growth Supplement, we used three reference
strains for growth performance: M. tuberculosis ATCC 27294, Mycobacterium kansasii ATCC 12478, and
Mycobacterium fortuitum ATCC 6441. Quality control of each
new batch of drug was performed with two reference strains, the H37Rv
strain of M. tuberculosis (ATCC 27294), susceptible to all
standard antituberculosis agents, and an M. tuberculosis INH-resistant strain (ATCC 35822).
Reproducibility testing.
To assess the reproducibility of
BACTEC MGIT 960 AST, a panel of 10 strains of M. tuberculosis with well-known susceptibility patterns was tested at
three separate cycles from two different sources of inoculum (six
replicates per strain). For each strain, the BACTEC MGIT 960 AST
results at both low and high drug concentrations were compared to the
expected results.
Resolution of discrepant results.
Isolates for which BACTEC
MGIT 960 AST results were discordant with those of BACTEC 460 TB were
sent blind to an arbiter site (National Reference Center of
Mycobacteria, Forschungszentrum Borstel) for confirmation. These
strains were tested by MOP on LJ medium, according to a standard
protocol (13).
Genetic analysis of drug resistance.
The isolates that had
discrepant results after BACTEC MGIT 960 AST and BACTEC 460 TB testing
were also examined to detect mutations in the genes responsible for
resistance to SM (rpsL and rrs), INH (katG,
inhA, and oxyR-ahpC), RMP (rpoB), and EMB (embB), as previously described (9).
Statistical analysis.
The statistical analyses were
performed using the Epi Info computer package (version 6.03; Centers
for Disease Control and Prevention, Atlanta, Ga.). P values
of
0.05 were considered significant.
 |
RESULTS |
Reproducibility of BACTEC MGIT 960 testing.
At first,
reproducibility assays were performed by testing 10 well-characterized
M. tuberculosis strains in triplicate from two separately
prepared inocula. Agreement of 99.5% was obtained for all four drugs
in a total of 420 tests, with only two incorrect results for
low-concentration EMB.
Testing of clinical isolates.
In the second phase of the
study, 78 M. tuberculosis clinical isolates were tested by
BACTEC MGIT 960 and BACTEC 460 TB for susceptibility to SM, INH, RMP,
and EMB. Out of a total of 546 tests, we found 9 (1.6%) discordant
results (Table 1). Of the 78 strains
tested for susceptibility to low-concentration SM, agreement between
the methods was found for 76 (97.4%) isolates (74 susceptible and 2 resistant). We found two strains determined to be resistant by BACTEC
MGIT 960 and susceptible by BACTEC 460 TB. When all the strains were
tested against SM (high concentration), they were found susceptible by
BACTEC 460 TB, while one isolate remained resistant according to BACTEC
MGIT 960 and susceptible according to BACTEC 460 TB. For
low-concentration INH, results by BACTEC 460 TB and BACTEC MGIT 960 agreed for 77 (98.7%) isolates (60 susceptible and 17 resistant). One
strain was resistant by BACTEC MGIT 960 and susceptible by BACTEC 460 TB. When the strains were tested against INH (high concentration), we
found 73 strains susceptible and 3 resistant according to both methods,
while two isolates were found resistant by BACTEC MGIT 960 only. For
results against EMB (low concentration), the two methods agreed for 75 (96.2%) isolates (64 susceptible and 11 resistant). For three isolates
(resistant according to BACTEC MGIT. 960 and susceptible according to
BACTEC 460 TB), results were discordant. With EMB (high concentration),
76 isolates were susceptible and only 2 were resistant according to
both methods, with no discordant results. Obviously, the strains
resistant to high concentrations of drugs were resistant to low
concentrations too. Finally, full agreement (100%) between both
methods was found for RMP results, with all of the isolates susceptible
(Table 1).
Table 1 also shows the accuracy and reliability of BACTEC MGIT 960, compared with BACTEC 460 TB, for the four drugs tested. Sensitivity,
i.e., the ability to detect true resistance, was 100% for all drugs
(data for RMP and high-concentration SM were not valuable because
resistant isolates were not found); specificity, i.e., the ability to
detect true susceptibility, ranged from 95.5% (for EMB at 5.0 µg/ml)
to 100% (for EMB [7.5 µg/ml] and RMP). When the nine discordant
results were further analyzed by isolate, we found that these
disagreements came from only three isolates. All the strains were found
resistant by BACTEC MGIT 960 and susceptible by BACTEC 460 TB; in
particular, discrepancies were observed with high-concentration SM,
low-concentration INH, and low-concentration EMB for the isolate R076
and with low-concentration SM, high-concentration INH, and
low-concentration EMB for the other two isolates, R077 and R078. These
isolates with discordant results were tested by conventional MOP on LJ
medium. As shown in Table 2, MOP agreed with BACTEC MGIT 960 for five of the nine discordant results and with
BACTEC 460 TB for the remaining discrepancies. Particularly, by MOP
testing the R076 isolate was found resistant to high-concentration SM,
while the isolates R077 and R078 were resistant to low-concentration SM
and high-concentration INH. Thus, five of the nine false-resistant results by BACTEC MGIT 960 were resolved as "true resistant." With
the resolved results, the specificity of BACTEC MGIT 960 was raised to
100% for low- and high-concentration SM and high-concentration INH
compared to BACTEC TB 460, while there were still four discrepant results (one low-concentration INH and three low-concentration EMB).
In addition, for these isolates, we analyzed the genes involved in the
resistance to SM, INH, and EMB (Table 3).
We found mutations in rpsL (K43R) for one isolate (R076) and
in katG (S315T) for the other two isolates (R077 and R078).
Finally, the time to report results ranged from 4.6 to 13.2 days
(median, 7.9 days) for BACTEC MGIT 960 and from 6 to 10 days (median,
7.3 days) for BACTEC 460 TB; the observed differences were
statistically not significant (P > 0.05).
 |
DISCUSSION |
In the last decade, the increasing number of drug-resistant
strains of M. tuberculosis has stimulated several efforts to
develop rapid and accurate nonradiometric methods for AST
(33). The MGIT can be considered the materialization of
these efforts, and at present in Europe, the manual version of the
system is used as a reliable method for susceptibility testing of
M. tuberculosis (4). It is conceivable that the
fully automated BACTEC MGIT 960, recently developed, could be a
promising alternative to the BACTEC 460 TB radiometric system, which is
still the widely used method providing susceptibility results in the
shortest possible time. The instrument's software algorithms evaluate
relative growth in the drug-containing tube and compare it to the
drug-free GC tube, and the results are interpreted automatically. A
strain is defined as resistant if the relative growth in the
drug-containing tube equals or exceeds that in the GC tube and
susceptible if the relative growth in the tube with drug is less than
in the GC tube. MGIT has several advantages over the BACTEC 460 TB
system, having no radioactivity (special safety and regulatory
practices such as radioactive disposal are not required) and being
noninvasive (using screw-cap tubes eliminates the need for needles) and
labor saving (it is completely automatic and easy to use, with a few handling requirements).
For systems currently used to determine the susceptibility of M. tuberculosis to antimycobacterial agents, such as the radiometric method (BACTEC 460 TB) or MOP, two critical concentrations (low and
high) of the primary drugs (INH, SM, and EMB) have been defined (13). In many laboratories only the low (critical)
concentration is usually used in routine testing. However, it should be
favorable to test both concentrations of the drugs, because the report
of resistant at the low level, especially for INH, could erroneously lead the clinician to believe that the use of that drug would result in
a therapeutic failure, while in fact that isolate could be susceptible
at the higher concentration of INH (13). Moreover, in many
instances the testing of the low concentration does not correlate well
if it is compared with molecular testing for resistance. For EMB,
previous reports (2, 27) have demonstrated that mutations
in the embB gene are associated only with resistance at the
high concentration, although a subset of clinical isolates were found
with no embB mutation, while laboratory screening showed resistance at the high EMB concentration.
The MGIT concentrations of SM, INH, RMP, and EMB have been established
on the basis of MOP concentrations in 7H10 medium. Based on NCCLS
recommendations (18, 33), using MGIT with two concentrations of all primary drugs, with the exception of RMP, in two
steps, is foreseeable. First, test M. tuberculosis clinical isolates at the low or critical concentrations, and then test only
those strains which are found resistant in the first round.
In this study, we evaluated the performance (reproducibility, accuracy,
and reliability) of BACTEC MGIT 960 for determining the susceptibility
of M. tuberculosis to the four first-line drugs (SIRE), by
comparing its results with those of BACTEC 460 TB. Previously, Pfyffer
et al. reported preliminary results of a similar evaluation (Abstr.
100th Gen. Meet. Am. Soc. Microbiol., abstr. C16, 2000). In
their study, the susceptibility data obtained by using BACTEC MGIT 960 compared well with those for BACTEC 460 TB, suggesting that the new
system was able to provide the clinician with rapid and reliable AST results.
There were only 3 strains, out of a total 78 tested, with nine
discordant results: one isolate for SM (4.0 µg/ml), INH (0.1 µg/ml), and EMB (5.0 µg/ml) and two isolates for SM (1.0 µg/ml), INH (0.4 µg/ml), and EMB (5.0 µg/ml). All the discordant results showed resistance with BACTEC MGIT 960 and were found susceptible by
the radiometric method. The arbiter results by MOP confirmed resistance
and resolved the discrepancies in five cases, to high-concentration SM
for the first strain and to low-concentration SM and high-concentration INH for the other two. Interestingly, the genetic analysis performed on
these strains in order to detect mutations in the genes involved in the
resistance against SM and INH reinforced the finding of resistant
strains obtained by BACTEC MGIT 960 and MOP (in LJ medium). In fact, we
found an S315T mutation in the katG gene of the R077 and
R078 strains and a K43R mutation in the rpsL gene of the
R076 strain. These mutations are known to be associated with resistance to INH and SM, respectively (10, 16, 17, 30). On the other hand, no mutations were observed in the embB gene of the
three strains, in the rrs and rpsL genes of R077
and R078 strains, and in the inhA, oxyR-ahpC, and
katG genes of strain R076; these findings were in agreement
with the MOP results. These data indicate that it is possible to define
the R077 and R078 strains as truly resistant to INH and the R076 strain
as truly resistant to SM, while the three strains can be considered
truly susceptible to low-concentration EMB and the R076 strain can be
considered truly susceptible to INH. After resolution by the arbiter
results, the specificity of BACTEC MGIT 960 increased. The turnaround
times for reporting results for the two systems were also found very
close, with no significant difference.
In conclusion, our data demonstrate that the BACTEC MGIT 960 gave good
reproducibility; it performed as well as BACTEC 460 TB in AST and can
be a valid alternative to the radiometric system under routine
laboratory testing.
 |
ACKNOWLEDGMENTS |
We thank Salman H. Siddiqi for critical reading of the manuscript
and for helpful suggestions and C. Muscas for technical assistance.
This work was supported in part by a grant from the National Program
"Tubercolosi" by Istituto Superiore di Sanità (contract no.
93-99/D/T6) and by a grant from Università Cattolica del Sacro Cuore.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Istituto di
Microbiologia, Largo F. Vito, 1, 00168 Rome, Italy. Phone: 39 06 30154964. Fax: 39 06 3051152. E-mail:
msanguinetti{at}rm.unicatt.it.
 |
REFERENCES |
| 1.
|
Alcaide, F.,
M. A. Benitez,
J. M. Escriba, and R. Martin.
2000.
Evaluation of the BACTEC MGIT 960 and the MB/BacT systems for recovery of mycobacteria from clinical specimens and for species identification by DNA AccuProbe.
J. Clin. Microbiol.
38:398-401[Abstract/Free Full Text].
|
| 2.
|
Alcaide, F.,
G. E. Pfyffer, and A. Telenti.
1997.
Role of embB in natural and acquired resistance to ethambutol in mycobacteria.
Antimicrob. Agents Chemother.
41:2270-2273[Abstract].
|
| 3.
|
Ardito, F.,
M. Sanguinetti,
L. Sechi,
B. Posteraro,
L. Masucci,
G. Fadda, and S. Zanetti.
2000.
Comparison of the mycobacteria growth indicator tube with radiometric and solid culture for isolation of mycobacteria from clinical specimens and susceptibility testing of Mycobacterium tuberculosis.
New Microbiol.
23:151-158[Medline].
|
| 4.
|
Bergmann, J. S.,
G. Fish, and G. L. Woods.
2000.
Evaluation of the BBL MGIT (Mycobacterial growth indicator tube) AST SIRE system for antimycobacterial susceptibility testing of Mycobacterium tuberculosis to 4 primary antituberculous drugs.
Arch. Pathol. Lab. Med.
124:82-86[Medline].
|
| 5.
|
Bergmann, J. S., and G. L. Woods.
1997.
Mycobacterial growth indicator tube for susceptibility testing of Mycobacterium tuberculosis to isoniazid and rifampin.
Diagn. Microbiol. Infect. Dis.
28:153-156[CrossRef][Medline].
|
| 6.
|
Bergmann, J. S., and G. L. Woods.
1997.
Reliability of mycobacteria growth indicator tube for testing susceptibility of Mycobacterium tuberculosis to ethambutol and streptomycin.
J. Clin. Microbiol.
35:3325-3327[Abstract].
|
| 7.
|
Centers for Disease Control and Prevention.
1992.
National action plan to combat multidrug-resistant tuberculosis.
Morb. Mortal. Wkly. Rep.
41(RR-11):5-48.
|
| 8.
|
Chew, W. K.,
R. M. Lasaitis,
F. A. Schio, and G. L. Gilbert.
1998.
Clinical evaluation of the Mycobacteria Growth Indicator Tube (MGIT) compared with radiometric (Bactec) and solid media for isolation of Mycobacterium species.
J. Med. Microbiol.
47:821-827[Abstract].
|
| 9.
|
Cingolani, A.,
A. Antinori,
M. Sanguinetti,
L. Gillini,
A. De Luca,
B. Posteraro,
F. Ardito,
G. Fadda, and L. Ortona.
1999.
Application of molecular methods for detection and transmission analysis of Mycobacterium tuberculosis drug resistance in patients attending a reference hospital in Italy.
J. Infect. Dis.
179:1025-1029[CrossRef][Medline].
|
| 10.
|
Cooksey, R. C.,
G. P. Morlock,
A. McQueen,
S. E. Glickman, and J. T. Crawford.
1996.
Characterization of streptomycin resistance mechanisms among Mycobacterium tuberculosis isolates from patients in New York City.
Antimicrob. Agents Chemother.
40:1186-1188[Abstract].
|
| 11.
|
Hanna, B. A.,
A. Ebrahimzadeh,
L. B. Elliott,
M. A. Morgan,
S. M. Novak,
S. Rusch-Gerdes,
M. Acio,
D. F. Dunbar,
T. M. Holmes,
C. H. Rexer,
C. Savthyakumar, and A. M. Vannier.
1999.
Multicenter evaluation of the BACTEC MGIT 960 system for recovery of mycobacteria.
J. Clin. Microbiol.
37:748-752[Abstract/Free Full Text].
|
| 12.
|
Heifets, L.,
T. Linder,
T. Sanchez,
D. Spencer, and J. Brennan.
2000.
Two liquid medium systems, Mycobacteria Growth Indicator Tube and MB Redox tube, for Mycobacterium tuberculosis isolation from sputum specimens.
J. Clin. Microbiol.
38:1227-1230[Abstract/Free Full Text].
|
| 13.
|
Inderlied, C. B., and M. Salfinger.
1999.
Antimycobacterial agents and susceptibility tests, p. 1601-1623.
In
P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 7th ed. ASM Press, Washington, D.C.
|
| 14.
|
Katila, M. L.,
P. Katila, and R. Erkinjuntti-Pekkanen.
2000.
Accelerated detection and identification of mycobacteria with MGIT 960 and COBAS AMPLICOR systems.
J. Clin. Microbiol.
38:960-964[Abstract/Free Full Text].
|
| 15.
|
Kent, P. T., and G. P. Kubica.
1985.
Public health mycobacteriology. A guide for the level III laboratory.
Centers for Disease Control, Atlanta, Ga.
|
| 16.
|
Musser, J. M.
1995.
Antimicrobial agent resistance in mycobacteria: molecular genetic insights.
Clin. Microbiol. Rev.
8:496-514[Abstract].
|
| 17.
|
Musser, J. M.,
V. Kapur,
D. L. Williams,
B. N. Kreiswirth,
D. van Soolingen, and J. D. van Embden.
1996.
Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance.
J. Infect. Dis.
173:196-202[Medline].
|
| 18.
|
National Committee for Clinical Laboratory Standards.
1995.
Antimycobacterial susceptibility testing for Mycobacterium tuberculosis. Tentative standard M24-T.
National Committee for Clinical Laboratory Standards, Wayne, Pa.
|
| 19.
|
Pablos-Mendez, A.,
M. C. Raviglione,
A. Laszlo,
N. Binkin,
H. L. Rieder,
F. Bustreo,
D. L. Cohn,
C. S. Lambregts-van Weezenbeek,
S. J. Kim,
P. Chaulet, and P. Nunn.
1998.
Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.
N. Engl. J. Med.
338:1641-1649[Abstract/Free Full Text].
|
| 20.
|
Palaci, M.,
S. Y. Ueki,
D. N. Sato,
M. A. da Silva Telles,
M. Curcio, and E. A. Matheus Silva.
1996.
Evaluation of mycobacteria growth indicator tube for recovery and drug susceptibility testing of Mycobacterium tuberculosis isolates from respiratory specimens.
J. Clin. Microbiol.
34:762-764[Abstract].
|
| 21.
|
Reisner, B. S.,
A. M. Gatson, and G. L. Woods.
1995.
Evaluation of mycobacteria growth indicator tubes for susceptibility testing of Mycobacterium tuberculosis to isoniazid and rifampin.
Diagn. Microbiol. Infect. Dis.
22:325-329[CrossRef][Medline].
|
| 22.
|
Rüsch-Gerdes, S.,
C. Domehl,
G. Nardi,
M. R. Gismondo,
H.-M. Welscher, and G. E. Pfyffer.
1999.
Multicenter evaluation of the Mycobacteria Growth Indicator Tube for testing susceptibility of Mycobacterium tuberculosis to first-line drugs.
J. Clin. Microbiol.
37:45-48[Abstract/Free Full Text].
|
| 23.
|
Sanguinetti, M.,
B. Posteraro,
F. Ardito,
S. Zanetti,
A. Cingolani,
L. Sechi,
A. De Luca,
L. Ortona, and G. Fadda.
1998.
Routine use of PCR-reverse cross-blot hybridization assay for rapid identification of Mycobacterium species growing in liquid media.
J. Clin. Microbiol.
36:1530-1533[Abstract/Free Full Text].
|
| 24.
|
Siddiqi, S. H.
1995.
BACTEC 460 TB System. Product and procedure manual, revision D.
Becton Dickinson Microbiology System, Sparks, Md.
|
| 25.
|
Siddiqi, S. H.,
J. E. Hawkins, and A. Laszlo.
1985.
Interlaboratory drug susceptibility testing of Mycobacterium tuberculosis by a radiometric procedure and two conventional methods.
J. Clin. Microbiol.
22:919-923[Abstract/Free Full Text].
|
| 26.
|
Siddiqi, S. H.,
J. P. Libonati, and G. Middlebrook.
1981.
Evaluation of rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis.
J. Clin. Microbiol.
13:908-912[Abstract/Free Full Text].
|
| 27.
|
Sreevatsan, S.,
K. E. Stockbauer,
X. Pan,
B. N. Kreiswirth,
S. L. Moghazeh,
W. R. Jacobs, Jr.,
A. Telenti, and J. M. Musser.
1997.
Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations.
Antimicrob. Agents Chemother.
41:1677-1681[Abstract].
|
| 28.
|
Tenover, F. C.,
J. T. Crawford,
R. E. Huebner,
L. J. Geiter,
C. R. Horsburgh, Jr., and R. C. Good.
1993.
The resurgence of tuberculosis: is your laboratory ready?
J. Clin. Microbiol.
31:767-770[Free Full Text].
|
| 29.
|
Tortoli, E.,
P. Cichero,
C. Piersimoni,
M. T. Simonetti,
G. Gesu, and D. Nista.
1999.
Use of BACTEC MGIT 960 for recovery of mycobacteria from clinical specimens: multicenter study.
J. Clin. Microbiol.
37:3578-3582[Abstract/Free Full Text].
|
| 30.
|
van Soolingen, D.,
P. E. de Haas,
H. R. van Doorn,
E. Kuijper,
H. Rinder, and M. W. Borgdorff.
2000.
Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands.
J. Infect. Dis.
182:1788-1790[CrossRef][Medline].
|
| 31.
|
Walters, S. B., and B. A. Hanna.
1996.
Testing of susceptibility of Mycobacterium tuberculosis to isoniazid and rifampin by mycobacterium growth indicator tube method.
J. Clin. Microbiol.
34:1565-1567[Abstract].
|
| 32.
|
Whyte, T.,
B. Hanahoe,
T. Collins,
G. Corbett-Feeney, and M. Cormican.
2000.
Evaluation of the BACTEC MGIT 960 and MB BAC/T systems for routine detection of Mycobacterium tuberculosis.
J. Clin. Microbiol.
38:3131-3132[Free Full Text].
|
| 33.
|
Woods, G. L.
2000.
Susceptibility testing for mycobacteria.
Clin. Infect. Dis.
31:1209-1215[CrossRef][Medline].
|
Journal of Clinical Microbiology, December 2001, p. 4440-4444, Vol. 39, No. 12
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.12.4440-4444.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Shin, S. J., Collins, M. T.
(2008). Thiopurine Drugs Azathioprine and 6-Mercaptopurine Inhibit Mycobacterium paratuberculosis Growth In Vitro. Antimicrob. Agents Chemother.
52: 418-426
[Abstract]
[Full Text]
-
Garrigo, M., Aragon, L. M., Alcaide, F., Borrell, S., Cardenosa, E., Galan, J. J., Gonzalez-Martin, J., Martin-Casabona, N., Moreno, C., Salvado, M., Coll, P.
(2007). Multicenter Laboratory Evaluation of the MB/BacT Mycobacterium Detection System and the BACTEC MGIT 960 System in Comparison with the BACTEC 460TB System for Susceptibility Testing of Mycobacterium tuberculosis. J. Clin. Microbiol.
45: 1766-1770
[Abstract]
[Full Text]
-
Mohammadzadeh, A., Farnia, P., Ghazvini, K., Behdani, M., Rashed, T., Ghanaat, J.
(2006). Rapid and low-cost colorimetric method using 2,3,5-triphenyltetrazolium chloride for detection of multidrug-resistant Mycobacterium tuberculosis.. J Med Microbiol
55: 1657-1659
[Abstract]
[Full Text]
-
Kruuner, A., Yates, M. D., Drobniewski, F. A.
(2006). Evaluation of MGIT 960-Based Antimicrobial Testing and Determination of Critical Concentrations of First- and Second-Line Antimicrobial Drugs with Drug-Resistant Clinical Strains of Mycobacterium tuberculosis.. J. Clin. Microbiol.
44: 811-818
[Abstract]
[Full Text]
-
Piersimoni, C., Olivieri, A., Benacchio, L., Scarparo, C.
(2006). Current Perspectives on Drug Susceptibility Testing of Mycobacterium tuberculosis Complex: the Automated Nonradiometric Systems. J. Clin. Microbiol.
44: 20-28
[Full Text]
-
Zanetti, S., Bua, A., Delogu, G., Pusceddu, C., Mura, M., Saba, F., Pirina, P., Garzelli, C., Vertuccio, C., Sechi, L. A., Fadda, G.
(2005). Patients with Pulmonary Tuberculosis Develop a Strong Humoral Response against Methylated Heparin-Binding Hemagglutinin. CVI
12: 1135-1138
[Abstract]
[Full Text]
-
Takakura, S., Tsuchiya, S., Fujihara, N., Kudo, T., Iinuma, Y., Mitarai, S., Ichiyama, S., Yasukawa, K., Ishiguro, T.
(2005). Isothermal RNA Sequence Amplification Method for Rapid Antituberculosis Drug Susceptibility Testing of Mycobacterium tuberculosis. J. Clin. Microbiol.
43: 2489-2491
[Abstract]
[Full Text]
-
Pina-Vaz, C, Costa-de-Oliveira, S, Rodrigues, A G
(2005). Safe susceptibility testing of Mycobacterium tuberculosis by flow cytometry with the fluorescent nucleic acid stain SYTO 16. J Med Microbiol
54: 77-81
[Abstract]
[Full Text]
-
Scarparo, C., Ricordi, P., Ruggiero, G., Piccoli, P.
(2004). Evaluation of the Fully Automated BACTEC MGIT 960 System for Testing Susceptibility of Mycobacterium tuberculosis to Pyrazinamide, Streptomycin, Isoniazid, Rifampin, and Ethambutol and Comparison with the Radiometric BACTEC 460TB Method. J. Clin. Microbiol.
42: 1109-1114
[Abstract]
[Full Text]
-
Adjers-Koskela, K., Katila, M.-L.
(2003). Susceptibility Testing with the Manual Mycobacteria Growth Indicator Tube (MGIT) and the MGIT 960 System Provides Rapid and Reliable Verification of Multidrug-Resistant Tuberculosis. J. Clin. Microbiol.
41: 1235-1239
[Abstract]
[Full Text]